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 12 
The availability of genome sequences of numerous organisms and the revolution brought about by 13 
genome editing (GE) tools (e.g., ZFNs, TALLENs, and CRISPR/Cas9 or RGENs) has provided a 14 
breakthrough in introducing targeted genetic changes both to explore emergent phenotypes and to 15 
introduce new functionalities. However, the wider application of these tools in biology, 16 
agriculture, medicine and biotechnology is limited by off-target mutation effects. In this review, 17 
we compare available methods for detecting, measuring and analyzing off-target mutations. 18 
Furthermore, we particularly focus on CRISPR/Cas9 regarding various methods, tweaks and 19 
software tools available to nullify off-target effects.  20 
Key words: ZFNs; TALENs; CRISPR/Cas9; genome editing; on-target; off-target; target 21 
specificity. 22 
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Sequence specific genome editing 25 
A recent revolution in sequence-specific programmable nucleases has led to the development of 26 
zinc-finger nucleases (ZFNs) (see Glossary), transcription activator-like effector nuclease 27 
(TALENs) and RNA-guided engineered nuclease (RGENs) derived from type II clustered, 28 
regularly interspaced, short palindromic repeats (CRISPR/Cas9). These nucleases have emerged 29 
as exciting tools to edit genes of interest with unprecedented control and accuracy in eukaryotic 30 
cells, paving the way for next-generation biotechnology. These GE tools cleave targeted 31 
chromosomal DNA by producing site-specific DNA double strand breaks (DSBs). The host 32 
endogenous DNA repair mechanism repairs DSBs via homologous recombination (HR) and non-33 
homologous end joining (NHEJ). The discovery of the most recent GE tools, particularly the 34 
CRISPR system, revolutionized genome engineering applications due to ease with which they can 35 
be adopted to target specific gene sequences. The basic details of different GE tools are listed in 36 
Glossary and Figure 1.  37 
GE tools have been highly appreciated for their numerous applications in biology, medicine, 38 
biotechnology and agriculture. These tools have attracted considerable attention from a broad 39 
range of research topics for their wider application, contributing to their selection as method of the 40 
year by Nature Methods in 2011 [1] and as a breakthrough of the year by Science in 2015 [2]. 41 
However, GE tools are limited by off-target mutations and each GE tools has its own pros and 42 
cons. In this review, we compare current GE tools for their off-target effects. Furthermore, we 43 
emphasize the best suitable GE technology, methods, tweaks and available software aimed to 44 
nullify off-target mutations. 45 
Specificity of GE tools 46 
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ZFN  47 
ZFNs consist of a nuclease domain derived from Fok1, a type of IIS restriction enzyme, and a 48 
DNA-binding domain [3]. These binding domains can be engineered to target specific DNA 49 
sequences. The Fok1 nuclease domain must dimerize to cleave DNA [4]; these Fok1s function as 50 
pairs contributing their high specificities. ZFNs recognize 18- to 36-bp DNA sequences; 51 
statistically, they form unique sites in many eukaryotic genome sizes. 52 
Compared to TALEN and CRISPR/Cas9, ZFNs are more expensive and laborious to design, and 53 
they use preferentially guanine-rich repeat (GNN) sequences, such as 5’-GNNGNNGNN-3’ which 54 
occurs rarely in most of the target sequences, thus limiting targetable sites [5, 6]. The use of ZFNs 55 
originated from publically available sources often causes cytotoxicity due to off-target effects [6] 56 
(Table-1). 57 
TALEN  58 
Similar to ZFNs, the second generation programmable nucleases, TALENs, consist of a nuclease 59 
domain derived from Fok1, but they have a distinct DNA-binding domain and employ 60 
transcription activator-like (TAL) effectors derived from the plant pathogen Xanthomonas sp. to 61 
cleave targeted DNA sequences[7, 8].  62 
TALENs recognize 30- to 40-bp DNA sequences, and they can be designed to target almost any 63 
DNA sequence, which represents a significant advantage over ZFNs and CRISPR/Cas9. TAL 64 
effector modules recognize single bases, whereas zinc fingers recognize 3-bp sub-sites, thus 65 
minimizing context-dependent DNA recognition and constituting a key advantage over ZFNs. 66 
Four different modules, each specific to one of the four bases, are used to construct TALENs. 67 
However, a TAL effector array often consists of 20 modules: it is time-consuming and laborious 68 
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to construct plasmids that encode TALENs. Although TALENs are not considered to be cytotoxic, 69 
they can induce off-target mutations like other GE tools [9]. However, off-target effects can be 70 
mitigated by designing unique target sequences that differ by at least 7 nucleotides from any other 71 
site in the human genome [10]. Researchers can also utilize a web-based resource 72 
(www.talenlibrary.net) to identify such unique sequences in the human genome. 73 
CRISPR/Cas9  74 
The third generation programmable nuclease, Cas9, is an RNA-guided DNA endonuclease that 75 
targets foreign DNA for destruction as part of a bacterial adaptive immune system mediated by 76 
CRISPR [11]. The specificity of CRISPR/Cas9, derived from S. pyogenesis bacteria, depends on 77 
gRNA, which hybridizes with 20-bp target DNA sequences, and Cas9, which recognizes 5’-NGG-78 
3’ sequences known as protospacer adjacent motifs (PAMs). CRISPR/Cas9 from other species 79 
recognize different PAMs, and their gRNAs are variable in size. Unlike ZFNs and TALENs, 80 
CRISPR/Cas9 are scalable and affordable, and the past two years of research on CRISPR/Cas9 81 
has been revolutionary in genome engineering. However, CRISPR/Cas9 can induce off-target 82 
mutations [11-14] and off-target chromosomal rearrangements [11], raising concerns for their 83 
wider application in medicine, agriculture and other biological sciences [12-15] (Table-1).  84 
Importance of target specificity 85 
GE tools lack target specificity; that is, they are able to target and bind the sequences in the genome 86 
that are similar but not identical, thus inducing undesirable genome modifications. Target 87 
specificity is a critical point for all GE tools for their broader application in biology, medicine and 88 
agriculture. GE tools can cut on-target sites efficiently, inducing site-specific DSBs in the genome, 89 
but they can also induce off-target mutations at sites homologous to on-target sites. Zinc finger 90 
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and TAL effector arrays can bind to highly homologous sites, resulting in on-target and off-target 91 
mutations, whereas both Cas9 and gRNAs can contribute to CRISPR/Cas9 off-target effects [5, 92 
16, 17].   93 
Off-target mutations may lead to cytotoxicity, apoptosis, and gross chromosomal rearrangements 94 
such as inversions, deletions, and translocations [16, 18-20]. Major concerns of off-target 95 
mutations have been observed in medical and clinical studies (Box - 1).  96 
One such example is a ZFN pair targeted to the C-C chemokine receptor 5 (CCR5) gene that 97 
encodes a co-receptor of human immunodeficiency virus (HIV) [21]. This ZFN pair also cleaves 98 
a highly homologous site in CCR2 gene, leading to ∼15-kbp chromosomal deletions, duplications 99 
and inversions of the intervening DNA segment in human cells [18, 19].  Nevertheless, off-target 100 
mutations in the CCR2 gene do not cause adverse side effects in patients with HIV infection. 101 
Another critical point to consider is that chromosomal re-arrangements are one of the hallmarks of 102 
cancer, which may activate oncogenes. Hence, off-target mutations should be monitored carefully 103 
to avoid such incidences.   104 
Assessing nuclease target specificities 105 
Several approaches have been developed to identify off-target sites of GE tools.  106 
SELEX 107 
The systematic evolution of ligands by exponential enrichment (SELEX) has been used to predict 108 
the sequences that GE tools prefer to bind [22]. Target DNA sequences in a pool of randomized 109 
oligonucleotide duplexes are identified after alternating cycles of ligand selection and 110 
amplification. 111 
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SELEX provides unbiased results of all of the potential off-target sites for a given GE tool, but 112 
most of the results obtained are based on experimental conditions. This in vitro technique does not 113 
consider several important factors such as chromatin structures and locus accessibility because 114 
semi randomized library oligodeoxynucleotide libraries are exposed to nucleases to identify the 115 
sequences that can be cleaved in vitro. 116 
In vivo methods 117 
Integrase-deficient lentiviruses (IDLVs) or adeno-associated viruses (AAVs) integrate at the sites 118 
of DSBs, which can be mapped to quantify off-target sites [23]. On the other hand, chromatin 119 
immunoprecipitation coupled with deep sequencing (Chip-Seq) can be used to track CRISPR/Cas9 120 
and map the binding sequences [24, 25]. In-vivo methods account for the chromatin structures and 121 
locus accessibility. However, IDLV capture is not sensitive enough to capture low-frequency off-122 
target sites. Chip-Seq using catalytically inactive or dead Cas9 (dCas) is limited by the fact that 123 
the DNA binding and cleavage events are uncoupled. Thus, Chip-seq fails to capture bona fide 124 
off-target sites, while producing many false positive sites [26, 27].   125 
In silico methods 126 
In silico methods are based on sequence homology rather than experimental data. Most of these 127 
programs list potential off-target sites with 3 or fewer mismatches [28]. These methods can be 128 
employed to synthesize nucleases on-target specific sequences while nullifying any off-target sites. 129 
Example of such in silico algorithm-based platforms are PROGNOS [29], which can be used for 130 
off-target prediction for ZFNs and TALENs; CRISPR design tools (http://crispr.mit.edu) for the 131 
CRISPR/Cas9 system; and CHOPCHOP (http://chopchop.re.fas.harvard.edu), an algorithm 132 
suitable for both CRISPR/Cas9 and TALEN off-target prediction. Although we have several in-133 
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vitro, in-vivo and in silico methods to analyze on- and off- target specificity, we still lack a 134 
comprehensive, unbiased, genome-wide method to identify on- and off- target sites created by GE 135 
tools. In the following section, we review recent progress made on unbiased genome-wide 136 
profiling of nuclease cleavage sites with special focus on the CRISPR/Cas9 system. 137 
Unbiased genome-wide profiling of nuclease cleavage sites including CRISPR/Cas9 138 
We and several other groups have used whole genome/exome sequencing (WGS/WES) to analyze 139 
the on- and off-target mutations in single cell-derived clones [Cho et al. Genome Res. 2014; Kim 140 
et al. Nature Methods 2015; Smith et al. Cell Stem Cell 15, 12 (2014); Veres et al. Cell Stem Cell 141 
15, 27 (2014)] or animals [Lyer et al. Nature Methods 12, 479 (2015)] and reported that off-target 142 
mutations are rarely induced by Cas9 or other GE tools. However, WGS are not sensitive enough 143 
to detect indels in a bulk population of cells. This sensitivity matters especially when GE tools are 144 
used for gene therapy or clinical studies, where millions of cells are treated with a nuclease. If one 145 
single cell has an oncogenic off-target mutation, it may lead to cancer. In order to address these 146 
issues, we and others have developed various methods for identifying genome-wide off-target sites 147 
in a bulk population of cells. Four different methods have been recently reported for unbiased 148 
genome wide comprehensive profiling of on- and off- target sites of CRISPR/Cas9 platform in a 149 
bulk population of cells (Figure-2). 150 
Genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq) 151 
This method represents an improvement over IDLV capture. Blunt-ended, double stranded 152 
phophothiorate oligodeoxynucleotides (dsODNs) are captured at on- and off- target DNA cleavage 153 
sites in cells. These dsODN integration sites are mapped in the genome via PCR amplification 154 
followed by deep sequencing [30]. 155 
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High-throughput genomic translocation sequencing (HTGTS) 156 
HTGTS exploits translocations that are induced in cells by erroneous ligations of on- and off-target 157 
sites in the genome. It uses on-target DSBs as a ‘bait’ to catch ‘prey’ sequences that are trans-158 
located to the on-target site. HTGTS is used to determine the prey sequences that corresponds to 159 
off-target sites [31]. Unlike other methods, HTGTS requires two concurrent DSBs, rather than one 160 
DSB, in a single cell. 161 
Breaks labelling, enrichments on streptavidin and next-generation sequencing (BLESS) 162 
BLESS is based on the principle of labelling DSBs present in the fixed cells using biotinylated 163 
oligonucleotides, which are then enriched and subjected to deep sequencing [32, 33]. BLESS 164 
provides a snapshot of DSBs at the time of cell fixation, resulting in poor sensitivity. 165 
Digested genome sequencing (Digenome-seq) 166 
Digenome-seq identifies off-target sites using nuclease digested genomic DNA (digenome) which 167 
is subjected to whole genome sequencing [34, 35]. In-vitro digestion of genomic DNA with Cas9 168 
or other nucleases yields sequence reads with the same 5’ ends at cleavage sites, which can be 169 
computationally identified using WGS data. 170 
Comparisons of genome-wide off-target profiling methods 171 
These methods can be classified based on whether DNA is cleaved in cells or in vitro and whether 172 
DSBs are captured in cells or in vitro (Table-2). Both GUIDE-seq and HTGTS are cell-based 173 
methods: DNA is cleaved in cells and DSBs are captured in cells. In contrast, Digenome-seq is an 174 
in vitro method using cell-free genomic DNA: DSB sites are identified computationally using 175 
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WGS data. BLESS is a method in between: DNA is cleaved in vivo but DSBs are captured in vitro 176 
after cell fixation.  177 
Cell-based methods are advantageous over Digenome-seq in that off-target DNA cleavage sites 178 
are identified in cells of interest under given experimental conditions. Off-target sites identified in 179 
one cell type may be different from those in other cell type, owing to the discrepancy in chromatin 180 
state or in nuclease expression levels. Because cell-free, chromatin-free genomic DNA is used, 181 
Digenome-seq cannot identify cell-specific off-target sites. In fact, Digenome-seq is more 182 
comprehensive than other methods, identifying many additional off-target sites [35].  183 
GUIDE-seq and Digenome-seq are highly sensitive, often capturing off-target sites with indel 184 
frequencies below 0.1%. BLESS is not sensitive because it provides a snapshot of DSBs at the 185 
time of cell fixation. HTGTS is limited by rare events of two concurrent DSBs, rather than one 186 
DSB, in a cell. GUIDE-seq is most quantitative: there is a good correlation between the numbers 187 
of captured sequence reads and mutations frequencies [30]. HTGTS is unlikely to be quantitative 188 
because translocation efficiencies are highly variable upon DSB sites. For example, intra-189 
chromosomal translocations tend to occur much more frequently than are inter-chromosomal 190 
translocations.  191 
Among the four methods, Digenome-seq is the only method without any pre-sequencing PCR steps. 192 
The other methods require oligonucleotide tag-specific amplifications (GUIDE-seq) or linear 193 
amplification-mediated (LAM)-PCR (HTGTS and BLESS), prior to high-throughput sequencing. 194 
To carry out BLESS, biotinylated oligonucleotide adaptors must be ligated to DSB ends in vitro. 195 
These steps are technically challenging and can also produce PCR primer-dependent artifacts or 196 
false positives.  197 
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Cell-based methods suffer from DSBs that occur spontaneously in the cells even in the absence of 198 
an engineered nuclease. GUIDE-seq, HTGTS and BLESS fails to distinguish these naturally-199 
occurring events resulting from nuclease-induced cleavages, resulting in false positives. 200 
Digenome-seq is not limited by naturally-occurring DSBs, which cannot produce uniform 201 
cleavage patterns, signatures of nuclease-induced events in vitro. Furthermore, DSB ends are 202 
trimmed or resected by endogenous repair enzymes in cells but not in vitro. To identify off-target 203 
sites using GUIDE-seq and HTGTS, bioinformatics filters are applied to search for sequences 204 
around the capture sites that are homologous to the on-target site. Up to 95% of captured sites are 205 
discarded during this filtering step. In contrast, Digenome-seq can pinpoint off-target sites because 206 
DSB ends are not processed in vitro. In addition, homology-based sequence search for off-target 207 
sites is unnecessary with Digenome-seq.  208 
Each programmable nuclease produces its own DSB pattern. SpCas9 yields blunt ends because 209 
it cuts both strands in a DNA molecule at the same position. ZFNs produce 5’ 4 or 5-nt overhangs 210 
because they cut the DNA molecule asymmetrically by leaving several single stranded bases. Cpf1 211 
and c2c1 is a recently identified RNA-guided nuclease derived from the class II CRISPR system 212 
that produces 5’ 5-nt overhangs [36, 37]. Blunt-ended oligonucleotides used in GUIDE-seq or 213 
BLESS may not be efficiently ligated with DSB ends. HTGTS and Digenome-seq are not limited 214 
by cohesive ends because no oligonucleotide tags are used. Both cohesive ends and blunt ends are 215 
resected in cells. As a result, the overhang patterns produced by a novel nuclease cannot be inferred 216 
by cell-based methods. Fortunately, these patterns are preserved in vitro and can be revealed by 217 
Digenome-seq. Finally, Digenome-seq is multiplexible without increasing sequencing depth [35]: 218 
Up to hundreds of guide RNAs can be mixed to digest cell-free genomic DNA in vitro.  219 
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It is of note that none of these methods are comprehensive. For example, one sgRNA specific to 220 
VEGF-A site has been tested by GUIDE-seq, HTGTS, and Digenome-seq [30, 31, 34], which 221 
revealed potential off-target sites that differed by up to 6 nucleotides from the on-target site. Off-222 
target sites with 5 or more mismatches cannot be chosen by in silico methods because there are 223 
more than thousands of such sites in the human genome. Importantly, most sites were identified 224 
commonly by all of the three methods. However, each method revealed potential off-target sites 225 
missed by other methods. Some of these sites could be false positives that arise from PCR primer-226 
dependent artifacts and naturally-occurring DSBs. To validate off-target sites, it is important to 227 
perform targeted deep sequencing and to detect nuclease-induced indels at candidate sites. 228 
Improving on-target specificity of CRISPR/Cas9 229 
Considering the recent progress made in last 2 years to improve the on-target specificity of 230 
CRISPR/Cas9 compared to ZFNs and TALENs, we focus on recent research updates for 231 
improving CRISPR/Cas9 on-target specificity (Figure -3).  232 
1. Target sequences 233 
This method designs unique target sequences that differ from any other site in the genome by at 234 
least 2 or 3 nucleotides in 20-nt sequences [12]. CRISPR/Cas9 discriminates efficiently against 235 
potential off-target sites with mismatched PAM sequences and seed regions upstream of the PAM 236 
sequence. Alternatively, a web-based computer algorithm (www.rgnome.net/casoffinder) can be 237 
used to search potential off-target sites and unique target sequences in more than 20 organism 238 
genomes, including the human genome. There are also several web-based tools (Table-3) to 239 
synthesize sgRNA with improved on-target specificity.  240 
2. Different versions of sgRNAs 241 
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Different versions of sgRNAs were synthesized to reduce off-target activity by an order of 242 
magnitude without sacrificing on-target specificity [12]. sgRNAs with two extra, target 243 
independent guanine nucleotides at the 5’ terminus can be less active at on-target sites but they are 244 
significantly more specific compared to conventional sgRNAs [12]. Truncated sgRNAs (tru-245 
sgRNAs) with 17 nts rather than 20 nts increases the specificity [38].  246 
3. Paired nickases and nickases 247 
Cas9 can be converted to a nickase that generate single-strand breaks rather than DSBs by mutating 248 
one of the nuclease active sites. Paired nickases generate two single-strand breaks or nicks on 249 
different DNA strands, resulting in a composite DSB and doubling the specificity of genome 250 
editing [12, 33, 39, 40]. Catalytically inactive or dead Cas9 (dCas9) created by inactivating two 251 
nuclease active sites is fused to the Fokl nuclease domain to make dimeric nucleases [41-43], 252 
similar to ZFNs or TALENs. The Fokl domain must dimerize to cleave DNA. Although these 253 
approaches are quite efficient to enhance the on-target specificity, they require two active sgRNAs 254 
to make functional pairs. In addition, target sequences must contain two PAM sequences in an 255 
inverted repeat configuration, limiting the choice of targetable sites. 256 
4. Cas9 protein and direct delivery of nucleases 257 
Using the Cas9 recombinant protein (commercially available from www.toolgen.com) rather than 258 
Cas9 encoding plasmid further reduces off-target mutations [44-47]. The direct delivery of Cas9-259 
sgRNA ribonucleoprotein (RNP) complexes induces mutations at target sites immediately after 260 
the delivery and decomposes rapidly by endogenous proteases, reducing off-target mutations 261 
without compromising on-target efficiency. 262 
5. Cas9 variants  263 
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Cas9 can be engineered to reduce off-target effects. Slaymaker et al. [48] replaced positively 264 
charged amino acid residues in Cas9 to weaken its interaction with a non-target DNA strand. 265 
Likewise, Kleinstiver et al. [49] mutated amino acid residues that form hydrogen bonds with the 266 
phosphate backbone. The resulting variants, termed enhanced SpCas9 (eSpCas9) and SpCas9 high 267 
fidelity (SpCas9-HF), respectively, showed genome-wide reduction of off-target effects.  268 
Consequently, two recent papers provided new insight into CRISPR/Cas9 targeting and specificity 269 
[50, 51]. These studies provided much needed answers to questions about the CRISPR/Cas9 target 270 
and specificity; according to these reports, CRISPR/Cas9 performs three checks before cutting the 271 
target sequences. Cas9 exerts specific control: once it binds to a region of DNA, it performs another 272 
check before bringing two section of the Cas9 protein complex like “two blades of scissors” to 273 
precisely align the active sites that cut double stranded DNA [50, 51]. Alternatively, these active 274 
sites are consciously mispositioned at off-target sites, so that DNA cannot be cut. Furthermore, 275 
two different active region of Cas9 on either strand communicate via structural changes to ensure 276 
Cas9 to cut accurate and precise regions of target sequences. To support this hypothesis, recent 277 
studies on Cas9 variants with alanine substitution at various location showed reduced off-target 278 
activities [48]. These reports shed light on conformational control of Cas9 on-target specificity 279 
and help researchers to synthesize more specific Cas9 variants. 280 
 281 
Conclusion and future perspectives 282 
GE tools including CRISPR/Cas9 have revolutionized genome engineering, and a major goal is to 283 
develop therapeutic applications of GE tools, particularly CRISPR/Cas9, to treat and cure genetic 284 
human and animal diseases or to use them to modulate novel traits in agriculture. Before this 285 
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technology can be adapted in humans or other organisms, researchers all around the world are 286 
endeavoring to ensure its precision and accuracy in order to avoid any unintended consequences 287 
arising from off-target mutations. Hence, in the last two years, research on CRISPR/Cas9 has made 288 
remarkable progress in gene editing, with particular a focus in reducing off-target mutations 289 
without sacrificing on-target specificity (see Outstanding questions).  290 
In the future, researchers should emphasize the different versions of sgRNA synthesis; certain 291 
sgRNAs are remarkably specific, resulting in no measurable off-target effects, as revealed by 292 
Digenome-seq and GUIDE-seq. To better understand the specificity and accuracy of different 293 
versions of sgRNAs, it is important to profile the off-target effects of as many sgRNAs as possible 294 
at the genome-wide level. Currently available genome-wide off-target profiling methods can detect 295 
indel frequencies up to 0.01% to 1% (0.1% on average); a more sensitive, cost effective method is 296 
needed to detect indel frequencies below 0.01% in the entire genome to determine the efficiencies 297 
of the various sgRNAs.  298 
 299 
 300 
  301 
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Legend for figures 302 
Figure 1 – Overview of the nuclease-mediated genome engineering using ZFNs, TALENs and 303 
CRISPR/Cas9; ZFN is composed of zink-finger protein (ZFP) at the amino terminus and Fok1 304 
nuclease at the carboxyl terminus, target sequence of ZFN is typically 10-36 bp in length excluding 305 
spacers; TALEN is composed of transcription activator like effectors (TALEs) at the amino 306 
terminus and Fok1 nuclease at the carboxyl terminus, target sequence of ZFN is typically 30-40 307 
bp in length excluding spacers; CRISPR/Cas9 composed of Cas9 and a sgRNA, guide sequence in 308 
sgRNA is complementary to 20 bp of target DNA sequence (protospacers), next to the 5’-NGG- 309 
3’ (N represents any nucleotide) referred as protospacer adjacent motif (PAM) 310 
 311 
Figure 2 – Outline of four different methods of unbiased genome-wide profiling of nuclease 312 
cleavage sites; Integrase-deficient lentivirus (IDLV) capture or genome-wide, unbiased 313 
identification of DSBs enabled by sequencing (GUIDE-seq); High-throughput genomic 314 
translocation sequencing (HTGTS); Breaks labelling, enrichments on streptavidin and next-315 
generation sequencing (BLESS); In vitro nuclease-digested genome sequencing (Digenome-seq); 316 
DSB, double-strand break; ODN, oligodeoxynucleotide; sgRNA, small-guide RNA; WGS, whole-317 
genome sequencing; gDNA, genomic DNA. 318 
 16 
 
 319 
Figure 3 – Graphical representation of strategies to minimize off-target mutations in 320 
CRISPR/Cas9; A) SgRNA Variants; sgRNAs with two extra guanines (ggX20) or truncated 321 
sgRNAs (gX17) enhance the on-target specificity, compared to conventional sgRNAs (gX19 or 322 
gX20). B) Cas9 variants; Use of paired nickases to generate two single-strand breaks or nicks on 323 
different DNA strands. C) Method of delivery; Use of Cas9-sgRNA ribonucleoprotein (RNP) 324 
complexes, rather than the Cas9 and sgRNA-encoding plasmids enhances target specificity while 325 
significantly minimizing off-target activities with continuous expression of Cas9 and sgRNA from 326 
plasmids (Modified from Koo et al.) [5]. 327 
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 330 
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Table 1: Comparison of the limitations of GE tools 
 
 
 
    
             METHODS 
 
 
                    ZFNs 
 
                 TALENs 
 
          CRISPR/Cas9 
 
 
OFF-TARGET ACTIVITY 
 
 
        Low to moderate 
 
 
  Low 
 
 
Low to moderate 
 
 
EASE OF APPLICATION TO 
GENETARTE TARGETTED GENOME 
EDITING 
 
 
Laborious, difficult and 
substantial cloning protein 
engineering required 
 
 
Laborious, moderately difficult 
and substantial cloning 
required 
 
 
Easy, simple cloning steps 
required 
 
 
EASE OF MULTIPLEXING 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
High 
 
 
 
EASE OF GENERATING LARGE 
SCALE LIBRARIES  
 
Low; laborious and complex 
protein engineering required  
 
Moderate; laborious and 
substantial cloning required 
 
Easy; Simple oligo 
synthesis and cloning 
required 
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Table 2. Comparisons of various methods for profiling genome-wide nuclease off-target sites. 
 
Methods GUIDE-seq HTGTS BLESS Digenome-seq 
DNA cleaved in 
vivo or in vitro 
In vivo In vivo In vivo In vitro 
DSB captured in 
vivo or in vitro 
In vivo In vivo In vitro In vitro 
Quantitative? Yes No ? ? 
Sensitivity High Low Low High 
Pre-sequencing 
PCR required? 
Yes Yes Yes No 
Homology-
based search 
required? 
Yes Yes No No 
Compatible 
with cohesive 
ends? 
Less sensitive 
with cohesive 
ends 
Yes Yes Yes 
Overhang 
patterns 
inferred? 
No No ? Yes 
Multiplexible No No No Yes 
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Table 3 – Web-based tools for guide RNA synthesis. 
Tools Web address Throughput Input Scoring Support 
for 
Cas9 
nickase 
Application Species 
supported 
Ref 
SgRNA 
designer 
http://www.broadinstitute.org/rnai/public/
analysis-tools/sgrna-design 
Medium to 
high 
Sequen
ce 
Yes No Picks and 
ranks 
sgRNA 
sequences 
Human, 
mouse 
[52] 
Cas-
OFFinder/ 
Cas-
Designer 
http://www.rgenome.net/cas-offinder/ 
 
 http://rgenome.net/cas-designer/  
Medium to 
high 
Sequen
ce 
Yes No Fast and 
versatile 
algorithms 
based search 
for potential 
off-targets 
 
20 
[28, 
53] 
 
SSFinder https://code.google.com/archive/p/ssfinder/ High Sequen
ce 
No No High 
throughput 
prediction of 
CRISPR/Ca
s9 binding 
site from 
huge 
nucleotide 
dataset  
N/A [54] 
Cas9 
design 
http://cas9.cbi.pku.edu.cn/ Low Sequen
ce 
No No Find target 
sequences 
and OTs for 
single 
sequence 
10 [55] 
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CRISPR 
Multitarget
er 
http://www.multicrispr.net/  Low Gene 
symbol 
or 
sequenc
es 
Yes  No Algorithm 
based 
unique 
target 
sequence 
prediction 
from 
multiple 
genes or 
transcripts 
12 [56] 
ZiFit http://zifit.partners.org/ZiFiT/ Low Sequen
ce 
No Yes Find target 
sequences 
and OTs for 
single 
sequence 
 
9 
 
[57] 
E-CRISP http://www.e-crisp.org/E-CRISP/ Low Gene 
symbol 
or 
sequenc
es 
Yes Yes Added 
options for 
Cas9 
nickase 
design 
 
More than 
30 
 
 
[58] 
CRISPR 
Direct 
http://crispr.dbcls.jp/ Low Sequen
ce, 
transcri
pt or 
genome 
location 
Yes No Find target 
sequences 
with limited 
information 
on off-target 
sites 
 
 
20 
 
 
[59] 
CCTop http://crispr.cos.uni-heidelberg.de/ Low Sequen
ce 
Yes  Fast and 
easy to 
generate 
sgRNAs 
with 
comprehensi
ve 
information 
on- and off-
target sites 
 
 
15 
 
 
[60] 
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CROP-IT http://www.adlilab.org/CROP-
IT/homepage.html 
Low sgRNA Yes No Comprehens
ive off-
target details 
Mouse and 
human 
None 
CHOP 
CHOP 
https://chopchop.rc.fas.harvard.edu/ Medium Sequen
ce, 
transcri
pt or 
gene 
i.d. 
 Yes Easier and 
fast 
synthesizing 
sgRNAs 
with 
complete 
info OTs for 
a single 
target 
sequence 
 
 
20 
 
 
[61] 
Crispr.mit http://crispr.mit.edu/ Low to 
medium 
Sequen
ce or 
FASTA 
files 
Yes Yes Easier and 
faster with 
comprehensi
ve 
information 
on- and off- 
target. 
Provide 
option to 
synthesize 
paired 
sgRNAs for 
nickases 
 
 
15 
 
 
 
[15] 
GT-Scan http://gt-scan.braembl.org.au/gt-scan/ Low Sequen
ce or 
gene 
i.d. 
No  Find target 
sequence 
and OTs for 
single 
sequence 
 
20 
 
[62] 
Cas OT http://eendb.zfgenetics.org/casot/ Low to 
medium 
FASTA 
file 
Yes  Finds target 
sequences 
and OTs 
User 
specified 
 
[63] 
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Low: input format and run supports one gene at a time queries. Medium: Supports small batches of gene or tens to hundreds of 
sgRNAs queries. High: supports genome-scale queries. OTs; off-targets, MMs; mismatches 
 
WU-
CRISPR 
http://crispr.wustl.edu/ Low Sequen
ce or 
gene 
i.d. 
Yes  Finds 
efficient 
target site 
based on 
OTs 
Mouse and 
human 
 
[64] 
sgRNACas9 http://www.biootools.com/col.jsp?id=103 High Softwar
e 
package 
Yes  Finds target 
sequences 
with limited 
information 
on- and off-
target sites 
 
User 
specified 
 
 
[65] 
sgRNA 
Scorer 1.0 
https://crispr.med.harvard.edu/sgRNAScorer/ Low Sequen
ce or 
FASTA 
file 
Yes  Finds target 
sequence 
OTs and 
also 
provides 
information 
on on-target 
scoring 
 
 
12 
 
 
[66] 
Protospacer http://www.protospacer.com/ Medium to 
high 
Sequen
ce, gene 
i.d. and 
many 
other 
inputs 
Yes  Finds target 
sequence 
along with 
sgRNA 
ranking 
 
User 
specified 
 
 
[67] 
CRISPRsee
k 
http://www.bioconductor.org 
/packages/release/bioc/html/CRISPRseek.htm
l 
High Softwar
e 
package 
Yes Yes Performs 
OTs and 
target 
sequence for 
multiple 
sequences 
Several 
common 
genomes 
 
 
[68] 
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